NXY-059: Review of neuroprotective potential for acute stroke

Annals of Pharmacotherapy

Volumn 40, Issue 3, 2006, Pages 461-471

  Fong, Jeffrey J ^a   Rhoney, Denise H ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Cerovive; Neuroprotection; NXY 059; Stroke

Indexed keywords

ALTEPLASE; CLOMETHIAZOLE; DISUFENTON SODIUM; FIBRINOLYTIC AGENT; FREE RADICAL; LANICEMINE; LIVER ENZYME; N TERT BUTYL ALPHA PHENYLNITRONE; NEUROPROTECTIVE AGENT; NITRONE DERIVATIVE; PLACEBO; SODIUM CHLORIDE; TENECTEPLASE;

ALGORITHM; BACKACHE; BLEEDING; BRADYCARDIA; BRAIN DISEASE; BRAIN EDEMA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIZZINESS; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ENZYME BLOOD LEVEL; FATIGUE; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LUNG EMBOLISM; NAUSEA; NEUROPROTECTION; NONHUMAN; PAIN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; STROKE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

ACUTE DISEASE; ANIMALS; BENZENESULFONATES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; NEUROPROTECTIVE AGENTS; NITROGEN OXIDES;

EID: 33645059159     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E636     Document Type: Review

References (43)

1. Heart disease and stroke statistics-2004 update. Dallas: American Heart Association, 2003.
2. Adams RD, Victor M, Ropper AH. Cerebrovascular diseases. In: Adams RD, ed. Principles of neurology. 6th ed. New York: McGraw-Hill, 1997: 777-873.
3. Luer MS, Rhoney DH, Hughes M, Hatton J. New pharmacologic strategies for acute neuronal injury. Pharmacotherapy 1996;16:830-48.
4. Green AR. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin Exp Pharmacol Physiol 2002;29:1030-4.
5. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8.
6. Calabresi P, Cupini LM, Centonze D, Pisani F, Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol 2003;53:693-702.
7. Lyden P, Gunnar Wahlgren N. Mechanisms of action of neuroprotection in stroke. J Stroke Cerebrovasc Dis 2000;9(suppl 2):9-14.
8. Lemke M, Frei B, Ames BN, Faden AI. Decreases in tissue levels of ubiquinol-9 and -10, ascorbate and alpha-tocopherol following spinal cord impact trauma in rats. Neurosci Lett 1990;108:201-6.
9. Warner DS, Sheng H, Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 2004;207(pt 18):3221-31.
10. Hensley K, Carney JM, Stewart CA, Tabatabaie T, Pye Q, Floyd RA. Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int Rev Neurobiol 1997;40:299-317.
11. Green AR, Ashwood T, Odergren T, Jackson DM. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther 2003;100:195-214.
12. Maples KR, Ma F, Zhang YK. Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. Free Radic Res 2001;34:417-26.
13. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001;21:2-14.
14. Canevari L, Kuroda S, Bates TE, Clark JB, Siesjo BK. Activity of mitochondrial respiratory chain enzymes after transient focal ischemia in the rat. J Cereb Blood Flow Metab 1997;17:1166-9.
15. Yoshimoto T, Kristian T, Hu B, Ouyang YB, Siesjo BK. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res 2002;932:99-109.
16. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103-12.
17. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778-87.
18. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001;909:46-50.
19. Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003;34:2228-33.
20. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 2001;40:433-9.
21. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA. Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke 2002;33:1665-70.
22. Blasig IE, Mertsch K, Haseloff RF. Nitronyl nitroxides, a novel group of protective agents against oxidative stress in endothelial cells forming the blood-brain barrier. Neuropharmacology 2002;43:1006-14.
23. Zhang RL, Chopp M, Chen H, Garcia JH. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J Neurol Sci 1994;125:3-10.
24. Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res 1998;788:25-34.
25. Oark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg 1991;75:623-7.
26. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32:190-8.
27. Marshall JW, Green AR, Ridley RM. Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res 2003;972:119-26.
28. Dehouck MP, Cecchelli R, Richard Green A, Renftel M, Lundquist S. In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res 2002;955:229-35.
29. Kastrup A, Engelhorn T, Beaulieu C, de Crespigny A, Moseley ME. Dynamics of cerebral injury, perfusion, and blood-brain barrier changes after temporary and permanent middle cerebral artery occlusion in the rat. J Neurol Sci 1999;166:91-9.
30. Yoshimoto T, Kanakaraj P, Ying Ma J, et al. NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. Brain Res 2002;947:191-8.
31. Edenius C, Strid S, Borga O, Breitholtz-Emanulsson A, Lanbeck Vallen K, Fransson B. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. J Stroke Cerebrovasc Dis 2002;11:34-43.
32. Strid S, Borga O, Edenius C, Jostell KG, Odergren T, Weil A. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol 2002;58:409-15.
33. Lees KR, Sharma AK, Barer D, et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 2001;32: 675-80.
34. Lees KR, Barer D, Ford GA, et al. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482-7.
35. Safety and effectiveness of NXY-059 for the treatment of patients who have suffered from a stroke. www.clinicaltrials.gov/ct/show/NCT00061022?order=1 (accessed 2004 Nov 30).
36. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Eng J Med 2006;354:588-600.
37. Safety of NXY-059 for the treatment of patients who have suffered from a stroke. www.clinicaltrials.gov/ct/show/NCT00075959?order=2 (accessed 2004 Nov 30).
38. Ronchera CL, Hernandez T, Peris JE, et al. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 1993;15:375-9.
39. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26:421-38.
40. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002;33:1411-5.
41. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-26.
42. Wagner KR, Jauch EC. Extending the window for acute stroke treatment: thrombolytics plus CNS protective therapies. Exp Neurol 2004; 188:195-9.
43. Lapchak PA, Song D, Wei J, Zivin JA. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 2004;188:279-85.